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Momordica charantia (bitter gourd) has been used in the traditional system of medicine for the treatment of various diseases.
Anticancer activity of M. charantia extracts has been demonstrated by numerous in vitro and in vivo studies. In the present study,
we investigated the diﬀerentiation inducing potential of fractionated M. charantia seed extracts in human myeloid HL60 cells. We
found that the HL60 cells treated with the fractionated seed extracts diﬀerentiated into granulocytic lineage as characterized by
NBT staining, CD11b expression, and speciﬁc esterase activity. The diﬀerentiation inducing principle was found to be heat-stable,
and organic in nature. The diﬀerentiation was accompanied by a downregulation of c-myc transcript, indicating the involvement
of c-myc pathway, at least in part, in diﬀerentiation. Taken together these results indicate that fractionated extracts of M. charantia
seeds possess diﬀerentiation inducing activity and therefore can be evaluated for their potential use in diﬀerentiation therapy for
leukemia in combination with other inducers of diﬀerentiation.
1.Introduction
Acute myeloid leukemia (AML) is a complex disease, char-
acterized by abnormal diﬀerentiation and unlimited cellular
proliferation that develops due to the accumulation of genet-
ic and epigenetic alterations. Current treatments including
chemotherapeutic drugs, radiation, and stem cell transplan-
tation are associated with incomplete remission and side
eﬀects [1]. Therefore, there is a need to discover novel anti-
cancer drugs that are eﬀective and have minimal side-ef-
fects associated with the treatment. In traditional system of
medicine and folklores, plant-based formulations with po-
tential anticancer properties have been described [2, 3].
Investigating dietary compounds with potential chemopre-
ventive and anticancer activity has provided important leads
forthedevelopmentofclinicallyrelevantanticancerdrugs[3,
4] However, systematic scientiﬁc studies have been lacking to
understand the mechanism (s) of their anticancer activity.
In the present study, we have focused our attention on a
tropical plant, Momordica charantia L, belonging to Cucur-
bitaceae family that has been used in the traditional health
care world over and the ethnobotanical use of this medicinal
p l a n ti sw e l ld o c u m e n t e d[ 5, 6]. M. charantia has been
reported to possess a number of diverse medicinal proper-
tiessuchasantimicrobial,antidiabetic,antifertilityandabor-
tifacient activity [7–10]. Antigrowth properties of fraction-
ated M. charantia whole plant extracts were ﬁrst reported
by West et al. [11]. Subsequently, a number of growth
inhibitors have been isolated from M. charantia seeds and its
antiproliferative activity has been demonstrated in a variety
of tumor cell lines [8, 12–15]. M. charantia fruit extract
and its components have also been shown to be cytotoxic to
leukemic lymphocytes and induce antitumor activity in vivo
[8, 16, 17].
WhileantiproliferativeandantitumoractivityofM.char-
antia has been demonstrated, its diﬀerentiation inducing
potential in leukemic cell lines has not been investigated.
We have used human myeloid leukemic HL60 cells as an
in vitro system to test the diﬀerentiation inducing potential
of M. charantia and to elucidate the molecular mecha-
nisms involved in the diﬀerentiation process. HL60 cells
have been used for screening of compounds for their2 Evidence-Based Complementary and Alternative Medicine
antileukemic potential and to elucidate the molecular mech-
anisms involved in the diﬀerentiation process. Diﬀerent
compoundshavebeenreportedtoinduceHL60cellstowards
granulocytic, macrophagic, and monocytic lineage [18–21].
In the present study, we report for the ﬁrst time that the frac-
tionated M. charantia seed extract induced diﬀerentiation of
HL60 to granulocytes and thus has potential to be developed
as a therapeutic supplement.
2.MaterialandMethods
2.1. Cells and Reagents. The human promyelocytic leukemia
HL60 cells (ATCC#CCL240) were maintained in 1 × RPMI
1640 medium supplemented with fetal calf serum (FCS,
20%), penicillin (100U/mL), and streptomycin (100μg/mL)
and2mML-glutamineina5%CO2 humidiﬁedatmosphere.
The chemicals required for cell culture were procured from
Biological Industries, Israel. Other chemicals were from
standard commercial suppliers.
2.2. Extraction and Partial Puriﬁcation of M. charantia Seed
Extract. Seeds of M. charantia L. (Pusa Vishesh variety, de-
veloped, veriﬁed, and released by Indian Agriculture Re-
search Institute (IARI), Pusa, New Delhi [22]) were obtained
from IARI, Pusa, New Delhi. Decorticated seeds (100g) were
extracted in 75% ethanol containing 0.2N HCl and 1mM
PMSF. The crude extract was centrifuged at 20,000×gf o r
1hrat4 ◦C. The supernatant was evaporated to 1/4 volume
under reduced pressure followed by neutralization using
NH4OH. Diﬀerential fractionation of the extract (Mc-1, dry
weight ∼16.5g) thus obtained using 0.05M (NH4)2CO3
followed by centrifugation at 20,000×gf o r4 5 m i na t4 ◦C
resulted in the pellet (Mc-2, dry weight ∼2.3g) and super-
natant (Mc-3, dry weight ∼14.2g) fractions. All the fractions
were evaporated and resuspended in Milli-Q water prior to
use. The fraction Mc-2 was further fractionated using ace-
tone extraction (Mc-2Ac, dry weight ∼400mg). Protein was
estimated using Lowry’s method [23].
2.3. Cell Viability and Cell Proliferation Assay. Cell viability
of HL60 cells upon treatment with M. charantia fractions,
namely, Mc-1, Mc-2, Mc-3, and Mc-2Ac was assayed using
MTT essentially as described by Yedjou et al. [24]. HL60
cells were seeded in 96-well plate at an initial density
of 105 cells/mL. Diﬀerent concentrations M. charantia test
fractions (diluted in the medium) were added to the cells.
The blank sample contained medium only. The cells were
placed in humidiﬁed 5% CO2 incubator at 37◦C. After 72h
ofincubation,thecellswerecentrifugedat800rpm for5min
and the supernatant culture medium carefully aspirated. The
cells were given 2 washes with PBS, followed by addition
of 200μL fresh medium containing MTT (0.5mg/mL). The
cells were further incubated at 37◦Cf o r2 h ,f o l l o w e db y
centrifugationat800rpmfor5min.Themediumcontaining
MTT was carefully removed followed by addition of 100μL
DMSO to each well. The plate was incubated at room
temperature with shaking for 10min to solubilize formazan
crystals. The absorbance at 570nm was measured in a
microplate reader (Tecan, Switzerland). The amount of color
produced is directly proportional to the number of viable
cells. All assays were done in triplicates for each concentra-
tion and cell viability was estimated by using means + SD
values for each treatment. Cell viability was calculated using
MTT absorbance of the control and treated cells: % survival
= (mean value treated sample/mean value of untreated sam-
ple) ∗ 100.
Eﬀect of M. charantia fractions on cell proliferation
rate was determined by viable cell count using a hemo-
cytometer as described by Lee et al. [20]. Brieﬂy, HL60
cells (105 cells/mL) were plated in a 24-well plate and
incubated with diﬀerent fractions of M. charantia at a ﬁnal
concentration of 20μg/mL for 5 days. Viable cell counts were
determinedoneachdayposttreatmentusingtrypanbluedye
exclusion assay using a light microscope (Leica, Germany).
2.4. Diﬀerentiation of HL60 Cells. HL60 cells (2 × 105/mL)
were incubated with the test fractions at the indicated con-
centrations for diﬀerent time intervals. Cell diﬀerentiation
was assayed by NBT (Nitroblue tetrazolium) reduction,
Wright-Giemsa staining, speciﬁc and nonspeciﬁc esterase
activities, and by FACS analysis.
2.5. Nitroblue Tetrazolium (NBT) Reduction. NBT staining
was used to assay for HL60 cell diﬀerentiation essentially as
described earlier [25]. Approximately 200 cells in triplicates
were scored under a light microscope (Leica, Germany) for
each test sample. Extent of diﬀerentiation is expressed as
number of % NBT positive cells. The data corresponding
to the number of total NBT positive cells out of the
total cells counted for diﬀerent experiments are given in
Table 1 in supplementary material available online at doi:
10.1155/2012/732404.Thedatawereanalyzedusingone-way
ANOVA and Tukey post hoc test to compare the diﬀerence
between the treated and the untreated control. An alpha
value of <0.05 was considered to be signiﬁcant.
2.6. Wright-Giemsa Staining. Morphological changes in the
HL60 cells induced by the test samples were evaluated us-
ing Wright-Giemsa staining as per the manufacturer’s in-
structions (Sigma-Aldrich, USA). Diﬀerential cell count was
performed under a light microscope (Leica, Germany) from
at least 3 independent glass slides for each experimental time
point in triplicates.
2.7. Speciﬁc and Nonspeciﬁc Esterase Activity. Speciﬁc and
nonspeciﬁc esterase activities in the HL60 cell lysates of the
control and treated cells were estimated using cytochemical
kits as per manufacturer’s instruction (Sigma 91-A and 91-
C, Sigma-Aldrich, USA). The presence of granulation (red-
dish and blackish granulation indicating the speciﬁc and
nonspeciﬁc esterase, respectively) indicated the areas of en-
zyme activity, which was scored in a scale of 0 to +4, 0
indicating no staining, hence no enzyme activity and +4Evidence-Based Complementary and Alternative Medicine 3
indicating brilliant staining, and hence maximal enzyme
activity.
2.8. Analysis for CD11b Expression. Control and treated
HL60 cells (5 × 105 cells) washed with PBS containing 1%
FCS and 0.01% sodium azide were incubated for 30min
in fetal calf serum at 4◦C. Subsequently, FITC-conjugated
anti-human CD11b antibody (1μg/mL, eBiosciences, USA)
was added to the cells and incubated at 25◦Cf o r4 5 m i n
followed by washing with PBS. The cells were then ﬁxed in
1% paraformaldehyde and analyzed on Becton Dickinson
Flow cytometer. Isotypic control (Rat IgG2b) was also used
to check for nonspeciﬁc binding. The results were plotted
usingWinMdisoftware(FlowCoreFacility,ScrippsResearch
Institute; http://facs.scripps.edu/software.html).
2.9. Northern Blot Analysis of c-myc Transcript. HL60 cells (2
× 105 cells/mL) were treated with fractions Mc-2 and Mc-
2Ac(20μg/mLeach).TotalRNAfromthecontrolandtreated
cells was isolated on day 4 of the treatment using TRIzol
reagent (Life Technologies, USA) as per the manufacturer’s
instructions.Brieﬂy,totalRNA(10μgeach)isolatedfromthe
control and treated HL60 cells resolved on 1% formaldehyde
agarose gel was transferred onto nitrocellulose membrane
and subjected to Northern blotting using α-P32-dCTP-
labeledc-myc genespeciﬁcprobe[26]essentiallyasdescribed
earlier [27].
3. Results
3.1. Acid Ethanol Extractable Fractions of M. charantia Seeds
Induce Diﬀerentiation of HL60 Cells. Analysis of diﬀeren-
tiation in HL60 cells treated with fraction Mc-1 revealed
that it was capable of inducing diﬀerentiation as established
by an increase in number of NBT positive cells. Maximum
diﬀerentiation (∼30%) was observed at 10μg/mL of Mc-
1( Figure 1(a)). However, treatment with higher concentra-
tions of Mc-1 (20μg/mL) resulted only in 22–25% diﬀeren-
tiation. Further fractionation of Mc-1 into fractions Mc-2
and Mc-3 resulted in the enrichment of the diﬀerentiation-
inducing principle(s) in fraction Mc-2. Approximately 50%
cells stained positive with Mc-2 (10μg/mL) with no further
increase in diﬀerentiation at higher concentration (20μg/
mL). The fraction Mc-3 showed minimal diﬀerentiation
(Figure 1(a)).
In order to assess if the observed increase in NBT positive
cells is due to death of immature cells caused by the test
fractions, cytotoxicity analysis was carried out with the
fractions Mc-1, Mc-2, and Mc-3 of M. charantia. No eﬀect
on the cell viability was observed with any of the fractions
upto 100μg/mL (the maximum concentration tested; Figure
1(b)). These data indicate that the three fractions were non-
cytotoxic even at 5× concentrations than those used for
diﬀerentiation studies (Figure 1(a)). Similar results were also
obtained using Alamar blue reduction assay for cell survival.
Percentage reduction of Alamar blue in HL60 cells treated
with the three factions was comparable to the control cells
conﬁrmingthattheM.charantiafractionswerenoncytotoxic
(data not shown).
3.2. Time Course of Induction of Diﬀerentiation. To inves-
tigate the time kinetics of the diﬀerentiation induced by
fraction Mc-2, the HL60 cells were treated with Mc-2 at a
ﬁnal concentration of 20μg/mL and scored for NBT-positive
cells from day 1 to day 5 of the treatment. As evident from
Figure 1(c),d i ﬀerentiation was observed on day 3, which
increased further on day 4 after which no signiﬁcant change
in the percentage of diﬀerentiated cells was observed.
3.3. The Diﬀerentiation Inducing Component(s) Present in
Fraction Mc-2 Are Nonproteinaceous and Heat-Stable. In
ordertoestablishthenatureofthecomponent(s)responsible
for inducing diﬀerentiation, fraction Mc-2 was heat-treated
at 70◦C (Mc-2H) or protease-treated (Mc-2P) for 30min
prior to its use in diﬀerentiation. No signiﬁcant loss in
the diﬀerentiation inducing ability was observed by these
treatments when compared to fraction Mc-2 (Figure 1(d))
suggesting that the diﬀerentiation inducing principle(s) are
nonproteinaceous in nature.
Further since the principle(s) were found to be nonpro-
teinaceous in nature, diﬀerent concentrations of acetone ex-
tractable component(s) of fraction Mc-2 (designated as Mc-
2Ac) were tested for its diﬀerentiation inducing potential.
The fraction Mc-2Ac induced diﬀerentiation in a concentra-
tion- and time-dependent manner (Figures 2(a) and 2(b)).
The fraction Mc-2Ac showed higher diﬀerentiation inducing
potential. As evident from the data, fraction Mc-2 showed
between 50 and 53% diﬀerentiation at 10 and 20μg/mL,
whereas fraction Mc-2Ac was able to bring about 59%
diﬀerentiation even at 10μg/mL concentration (cf. Figures
1(a) and 2(a)). Like the parent fraction Mc-2, fraction Mc-
2Ac also did not show any cytotoxic eﬀect on HL60 cells even
at5×concentrationthanthatusedfordiﬀerentiation(Figure
2(c)).
3.4. Minimum Time Required for Fraction Mc-2Ac to Trigger
Diﬀerentiation. To determine the minimum time required
for the diﬀerentiation to be triggered by fraction Mc-2Ac,
the cells were grown in the medium containing fraction
Mc-2Ac (20μg/mL) for diﬀerent time period followed by
their growth in normal medium. Very low percentage of
cells was NBT-positive when the cells were grown in the
medium containing Mc-2Ac up to 48h (Figure 2(d)). A
signiﬁcant increase in the NBT-positive cells was recorded
when the cells were grown in the medium containing Mc-
2Ac for 72h. Further increase in the time for which the
fraction Mc-2Ac was present in the medium resulted in
further increase in the NBT-positive cells. The data suggest
that fraction Mc-2Ac is required to be present in the medium
f o ra tl e a s t7 2 ht ot r i g g e rd i ﬀerentiation. The cells show
maximum diﬀerentiation (∼55–59%) whenthe fraction Mc-
2Ac remained present in the medium for 96h.
3.5. Eﬀect of M. charantia Seed Fractions on HL60 Cells Pro-
liferation. Since many other inducers of diﬀerentiation are4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: (a) Eﬀects of diﬀerent fractions of M. charantia seeds on HL60 cells diﬀerentiation. HL60 cells treated with varying concentrations
of diﬀerent fractions were scored for the percentage of NBT positive cells on day 5. Mc-1-(5–10μg/mL) and Mc-2-(5–20μg/mL) treated cells
showed a signiﬁcant increase in NBT staining compared to untreated control. (b) Eﬀect of diﬀerent fractions of M. charantia seeds on HL-60
cell viability. HL60 cells (105 cells/mL) were cultured in 96-well plates and incubated with the indicated concentrations of fractions Mc-1,
Mc-2,andMc-3,for72h.TheMTTassaywasusedtoassesscellviability.Theopticaldensityvalueofthecontrolwasregardedas100%.Data
represent the mean ± SD of three independent experiments. (c) Time dependence of Mc-2 induced HL60 cells diﬀerentiation. Control, and
Mc-2 (20μg/mL) or DMSO-(included as a positive control) treated HL60 cells were scored for percentage of diﬀerentiation by NBT staining
from day 1 to 5. (d) Eﬀect of heat-inactivated Mc-2 (Mc-2H) and S. griseus protease-treated (Sigma Aldrich, USA) Mc-2 (Mc-2P) on HL60
cells diﬀerentiation. HL60 cells treated with indicated fractions (20μg/mL each) were scored for the NBT positive cells on day 5. All the three
fractions resulted in signiﬁcantly increased NBT staining, relative to untreated control. The data in all the panels represent mean ± SD of
three independent experiments performed in triplicates. ∗P<0.05, ∗∗P<0.01, and ∗∗∗P<0.001 relative to untreated control.
known to cause both diﬀerentiation and inhibit proliferation
[28–30], eﬀect of diﬀerent fractions of M. charantia was also
evaluated on proliferation of HL60 cells. As evident from
Figure 3, no change in rate of proliferation was noted till day
3 of the treatment, after which a slight decline in the cell
countwasobservedonday4andday5inthetreatedsamples,
when compared to the untreated control.
3.6. CD11b Expression in Mc-2Ac-Treated HL60 Cells Con-
ﬁrms Diﬀerentiation. Diﬀerentiation of HL60 cells treated
with Mc-2Ac was further conﬁrmed by analysis of expression
ofCD11b,amarkerofdiﬀerentiation.Anincreaseinthepre-
sence of CD11b positive cells could be detected in the Mc-
2Ac-treated HL60 cells from day 3 to day 5, evident by the
observed increase in the mean ﬂuorescent intensity, when
compared to untreated control (Figures 4(a) and 4(b)). Neg-
ligible staining was seen with isotype control and incubation
of cells with isotype control Mab did not change cd11b ex-
pression (data not shown). The percentage increase in the
expression of CD11b in Mc-2Ac-treated cells correlatedEvidence-Based Complementary and Alternative Medicine 5
P
e
r
c
e
n
t
 
N
B
T
-
p
o
s
i
t
i
v
e
 
c
e
l
l
s
80
70
60
50
40
30
20
10
Day 4
Day 5
0
0
51 0 2 0
Mc-2Ac conc. (µg/mL)
∗∗
∗∗
∗∗
∗∗
∗
∗
(a)
P
e
r
c
e
n
t
 
N
B
T
-
p
o
s
i
t
i
v
e
 
c
e
l
l
s
∗∗
∗∗
∗∗
∗
∗
∗
Control
DMSO (1%)
Mc-2 (20 µg/mL)
90
80
70
60
50
40
30
20
10
0
12345
Days
(b)
120
100
80
60
40
20
0
5 10 20 50 100
Concentration (µg/mL)
C
e
l
l
 
v
i
a
b
i
l
i
t
y
 
(
%
 
o
f
 
c
o
n
t
r
o
l
)
(c)
70
60
50
40
30
20
10
0
24 48 72 96 120
P
e
r
c
e
n
t
 
N
B
T
-
p
o
s
i
t
i
v
e
 
c
e
l
l
s
Time (h) in the presence of Mc-2Ac
∗∗∗
∗∗∗
∗
(d)
Figure 2: (a) Eﬀe c to fa c e t o n ee x t r a c to fM c - 2( M c - 2 A c )o nH L 6 0c e l l sd i ﬀerentiation. Mc-2Ac-treated (5–20μg/mL) cells showed a
signiﬁcant increase in NBT positive cells on day 4 and day 5, respectively, compared to untreated cells. (b) Time-dependence of Mc-2Ac-
induced HL60 cells diﬀerentiation. Mc-2Ac-treated HL60 cells were scored for NBT-positive cells from day 1 to 5. DMSO was included as
a positive control. (c) Eﬀect of fraction Mc-2Ac on HL60 cells viability. HL60 cells (105/mL) cultured in a 96-well plate were treated with
the indicated concentrations of fraction Mc-2Ac for 72h. Cell viability was assessed by MTT assay. The optical density values of untreated
control cells were taken as 100%. The data represent the mean + SD of three independent experiments. (d) Minimum time required for Mc-
2Ac to induce HL60 diﬀerentiation. HL60 cells cultured in the presence of Mc-2Ac (20μg/mL) for the indicated time, followed by growth in
the medium without Mc-2Ac, were scored for NBT-positive cells on day 5. Data in all the panels represent the mean ± S.D of 3 independent
experiments performed in triplicates. ∗P<0.05, ∗∗P<0.01, and ∗∗∗P<0.001 relative to untreated cells.
well with the number of NBT-positive cells from day 3 to
day 5.
3.7. The Acetone Extractable Fraction (Mc-2Ac) Diﬀerentiates
HL60 Cells into Granulocytes. HL60 cells are predominantly
promyelocytic in origin and can be induced to diﬀeren-
tiate into granulocytic or monocytic lineages by diﬀerent
inducers. Wright-Giemsa staining of the fractions Mc-2- and
Mc-2Ac-treated HL60 cells reveals the presence of HL60
cells of granulocytic lineage. Presence of segmented and
banded neutrophils in Mc-2Ac-treated cells is evident from
Figure 4(c).
Lineage of diﬀerentiation was further conﬁrmed by de-
termination of the speciﬁc/nonspeciﬁc esterase activity in
HL60 cells. The HL60 cells treated with either Mc-2 or Mc-
2Ac were found to be positive for speciﬁc esterase activity
( + 2t o+ 3 )a n dn e g a t i v e( 0 )f o rn o n s p e c i ﬁ ce s t e r a s ea c t i v i t y
conﬁrming to the granulocytic diﬀerentiation of the HL60
cells by M. charantia seed fractions.
3.8. Eﬀect of Fraction Mc-2Ac on c-myc Expression in HL60
Cells. Since c-myc expression has been reported to be down-
regulated in leukemic cells that were induced to diﬀerentiate
[31–33], c-myc transcript levels were measured in HL60
cells treated with fractions Mc-2 and Mc-2Ac on day 4
after treatment. Northern blot analysis performed with total
RNA isolated from the control and treated cells revealed
a signiﬁcant decrease in the levels of c-myc transcript6 Evidence-Based Complementary and Alternative Medicine
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Figure 3: The eﬀect of diﬀerent fractions of M. charantia seed
extract on the growth of HL60 cells. Cells were treated with diﬀer-
ent concentrations of fractions Mc-1, Mc-2, Mc-3 and Mc-2Ac
(each at 20μg/mL concentration) for 5 days. Viable cell count was
determined at diﬀerent posttreatment intervals. The data represent
means ± SD of three parallel experiments.
(2.1Kb) in the Mc-2Ac-treated HL60 cells when compared
to untreated control (Figure 5). These data suggest that the
diﬀerentiation induction by M. charantia seed fraction may,
in part, involve c-myc pathway.
4. Discussion
In the present study, we for the ﬁrst time demonstrate the
diﬀerentiation induction potential of the M. charantia seeds
in HL60 cells. It is clearly demonstrated that fraction Mc-1
and its subsequent fractions Mc-2 and Mc-2Ac are able to
diﬀerentiate HL60 cells. As Mc-1 is crude extract, a decrease
in the diﬀerentiated cells in Mc-1-treated cells at higher con-
centration (i.e., 20μg/mL) in comparison with that observed
with 10μg/mL could possibly be due to the presence of some
compounds that could inhibit diﬀerentiation and which gain
their inhibitory eﬀect when concentration is increased to
20μg/mL. Upon further fractionation into Mc-2 and Mc-
3, these inhibitors are fractionated away and that is why
no decrease in diﬀerentiation is seen in fractions Mc-2 at
20μg/mL. The test fractions of M. charantia capable of
inducing diﬀerentiation did not exhibit any cytotoxic eﬀect
on HL60 cells. These data suggest that the increase in NBT-
positive diﬀerentiated cells upon treatment is indeed due to
diﬀerentiation brought about by the M. charnatia fractions
and not caused by cell death of immature undiﬀerentiated
cells. Our results are in agreement with the reports put forth
bySharmaetal.,whoalsodidnotobserveanycytotoxiceﬀect
of ethanolic extract of M. charantia on a number of cancer
cells [34].
Unlike many other plant-derived compounds which in-
duce the HL60 cells towards monocytic or macrophagic
pathway [35, 36], fractionated M. charantia extracts induced
HL60 cells into granulocytic pathway, evident by the mor-
phologicalcharacteristicsofgranulocyticlineage,presenceof
speciﬁc esterase activity, and expression of CD11b in the Mc-
2- and Mc-2Ac-treated HL60 cells. Granulocytic diﬀerentia-
tion of HL60 cells by fractionated M. charantia seed extract
is comparable to that observed with retinoic acid [25].
Induction of diﬀerentiation of HL60 cells by fractionated
M. charantia seed extracts in a time- and concentration-de-
pendent manner supports the “all or none” response similar
to that of DMSO and sodium butyrate [37]a so p p o s e dt o
the graded response seen by another inducer of HL60 diﬀer-
entiation such as retinoic acid [25]. It is known that diﬀer-
ent inducers require diﬀerent lengthes of time to trigger dif-
ferentiation in diﬀerent cell types [38–40]. During this per-
iod, the cells become committed to diﬀerentiation and this
has been proposed to be a rate limiting step for the cells to
synthesize cellular constituents above a threshold value [41].
While diﬂuoromethylornithine (DFMO) is reported to trig-
ger diﬀerentiation of MEL cells when present in the medium
for only 24h, vitamin D3 is required to be present for 48h in
the medium to induce diﬀerentiation of MEL cells [40]. On
theotherhand,vitaminD3wasabletoinducediﬀerentiation
of HL60 cells on day 1 itself [38]. In the present study, it was
established that presence of Mc-2Ac for a minimum time of
∼72h is required to observe any signiﬁcant diﬀerentiation,
though some diﬀerentiation could be observed on day 2
also. Since the fraction Mc-2A did not show any cytotoxic
eﬀect even at 2.5× concentration that induced maximum
diﬀerentiation, it is advantageous over other inducers such
as DFMO or DMSO, that exhibit cytotoxic eﬀect at higher
concentration.
The nature of the diﬀerentiation inducing compound(s),
as established by the retention of the diﬀerentiation inducing
activity even after heat and protease treatment, is in line
with other studies wherein a large proportion of the inducers
of HL60 diﬀerentiation are nonproteinaceous in nature [35,
36]. The extent of diﬀerentiation induced with the Mc-2
and Mc-2Ac fractions is comparable with the diﬀerentiation
induced by many other plant-derived compounds [42].
M.charantiaseedfractionsdidnotexhibitanyantiprolif-
erative activity. Till day 3, there was no change in the growth
proﬁle of the treated cells when compared to the untreated
cells. Similar results have been obtained by induction of
diﬀerentiationofhumanK562cellswithhemin[43].Aslight
declineinthecellcountinMc-1,Mc-2,andMc-2Acfractions
on day 4 and day 5 of the treatment is due to induction
of diﬀerentiation as the diﬀerentiated cell population does
not proliferate further. These data suggest that the test
fractions do not possess antiproliferative activity. Although
M. charantia extracts have been reported to have antitumor
and antiproliferative activities ([13–16], for review please see
[10, 44]), most of such activities have been attributed to a
number of proteins identiﬁed as lectins—ribosome inacti-
vating proteins such as alpha momorcharin, momordin [7,
15, 45], and MAP30 ([8, 46], for review, please see [10, 44]).
Unlike these, the diﬀerentiation inducing fractions did notEvidence-Based Complementary and Alternative Medicine 7
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Figure 4: (a) Analysis of CD11b expression. Untreated control and Mc-2Ac- (20μg/mL) treated HL60 cells were analyzed for CD11b
expressing population by FACScan. (b) Mean ﬂuorescent intensity of CD11b expression in untreated control, and Mc-2Ac- (20μg/mL)
treated cells from day 3 to day 5. (c) Wright-Giemsa-stained untreated control and Mc-2Ac-treated HL60 cells on day 5 of the treatment.
Diﬀerentiated cells with distinct granulocytic features, that is, multilobular nuclei can be seen in Mc-2Ac-treated cells (40×).
exhibit any antiproliferative activity and the diﬀerentiation
inducing principle(s) was found to be nonproteinaceous in
nature, suggesting that the diﬀerentiation inducing factors of
M. charantia are diﬀerent from its antitumor factors.
Since HL60 cells are induced to diﬀerentiate by retinoic
acid, it was imperative to rule out the possibility that
the diﬀerentiation by M. charantia e x t r a c ti sn o td u et o
retinoic acid present in the extracts, if any. For this purpose,
diﬀerentiation inducing potential of the fraction Mc-1 was
assessed in K562 cells, prototype human myeloid leukemia
cell type that is resistant to retinoic acid induced diﬀeren-
tiation [28, 47] by morphological examination as described
earlier [48]. While treatment with positive inducer sodium
butyrate resulted in upto 85–90% cells to be diﬀerentiated,
fraction Mc-1 resulted in diﬀerentiation of ∼40–45% cells
(Ramani Soundararajan, Madhu Geeta, and Aparna Dixit,8 Evidence-Based Complementary and Alternative Medicine
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Figure 5: Northern blot analysis of c-myc expression in the control
(lanes 1 and 2), Mc-2-(lane 3), and Mc-2A-(lane 4) treated HL60
cells. Top panel shows the 2.1Kb c-myc transcripts. An identical
gel stained with ethidium bromide is included as loading control
(bottom panel).
unpublished data). Vitamin A levels have been reported to
be undetectable in methanolic extracts of M. charantia [49].
In the present study, seed extraction was performed with
acid ethanol, and therefore, it was unlikely to have retinoic
acid. Analysis of the test fractions Mc-1, Mc-2, Mc-3, and
Mc-2A for vitamin A content by LC-MS-MS conﬁrmed that
these fractions did not contain vitamin A (data not shown).
Thus, the ability of M. charantia seed extract to induce
diﬀerentiation of vitamin A resistant K562 cells and absence
of vitamin A in the test fractions of M. charantia suggest that
the diﬀerentiation brought about by these fractions in the
present study is not brought about by retinoic acid.
The transcription factor c-Myc plays a role in the control
of cell proliferation and diﬀerentiation [50]. A signiﬁcant
decrease in the c-myc expression in the Mc-2- and Mc-
2Ac-treated cells is in line with previous reports wherein
am o d u l a t i o ni nc-myc expression in HL60 cells induced
to diﬀerentiate has been established [31, 32]. Murine ery-
throleukemic (MEL) cells induced to diﬀerentiate by DMSO
also showed a biphasic change in the c-myc levels suggesting
that the changes in c-myc may be important for irreversible
commitmentofMELcellstowardsterminalerythroidlineage
[33]. The reduced expression of c-myc can be related to the
loss of proliferative potential of the diﬀerentiated cells [32].
A slight decrease in c-myc transcript in the Mc-2Ac-treated
cells relates well with the decrease in number of cells from
day 3 onwards, relating to the loss of proliferating potential
of the diﬀerentiated cells as c-Myc has been shown to be
functionally involved in DNA synthesis [51].
Thus, the present study for the ﬁrst time demonstrates
diﬀerentiation inducing activity of the fractionated M. cha-
rantia seed extracts which can be further assessed as inducer
of diﬀerentiation for the treatment of APL, either alone or
in combination with the suboptimal concentrations of other
known inducers of diﬀerentiation. Studies are in progress to
understandthemechanismbywhichthecompoundspresent
in fraction Mc-2Ac are inducing diﬀerentiation.
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